Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice (DOI:10.1016/j.neuron.2010.01.008);Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice

Neuron

Volumn 65, Issue 2, 2010, Pages 178-190

  Milnerwood, Austen J ^a,b   Gladding, Clare M ^a,b   Pouladi, Mahmoud A ^a,b,c   Kaufman, Alexandra M ^a,b   Hines, Rochelle M ^a,b   Boyd, Jamie D ^a,b   Ko, Rebecca W Y ^a,b   Vasuta, Oana C ^a,b   Graham, Rona K ^a,b,c   Hayden, Michael R ^a,b,c   Murphy, Timothy H ^a,b   Raymond, Lynn A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

humdisease; molneuro; signaling

Indexed keywords

CASPASE 6; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HUNTINGTIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CELL FRACTIONATION; CONTROLLED STUDY; CORPUS STRIATUM; ELECTRON MICROSCOPY; GENE MUTATION; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 74549181538     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2010.01.031     Document Type: Erratum

References (86)

1. Andre V.M., Cepeda C., Venegas A., Gomez Y., and Levine M.S. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J. Neurophysiol. 93 (2006) 2108-2119
2. Arnth-Jensen N., Jabaudon D., and Scanziani M. Cooperation between independent hippocampal synapses is controlled by glutamate uptake. Nat. Neurosci. 5 (2002) 325-331
3. Arundine M., and Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34 (2003) 325-337
4. Bliss T.V.P., and Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361 (1993) 31-39
5. Brown C.E., Li P., Boyd J.D., Delaney K.R., and Murphy T.H. Extensive turnover of dendritic spines and vascular remodeling in cortical tissues recovering from stroke. J. Neurosci. 27 (2007) 4101-4109
6. Carter A.G., and Regehr W.G. Prolonged synaptic currents and glutamate spillover at the parallel fiber to stellate cell synapse. J. Neurosci. 20 (2000) 4423-4434
7. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernández J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66 (2001) 525-539
8. Cepeda C., Hurst R.S., Altemus K.L., Flores-Hernández J., Calvert C.R., Jokel E.S., Grandy D.K., Low M.J., Rubinstein M., Ariano M.A., and Levine M.S. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J. Neurophysiol. 85 (2001) 659-670
9. Cepeda C., Wu N., André V.M., Cummings D.M., and Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 81 (2007) 253-271
10. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 83 (2007) 228-248
11. Chen S., and Diamond J.S. Synaptically released glutamate activates extrasynaptic NMDA receptors on cells in the ganglion cell layer of rat retina. J. Neurosci. 22 (2002) 2165-2173
12. Chen H.S., and Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97 (2006) 1611-1626
13. Clark B.A., and Cull-Candy S.G. Activity-dependent recruitment of extrasynaptic NMDA receptor activation at an AMPA receptor-only synapse. J. Neurosci. 22 (2002) 4428-4436
14. Cowan C.M., and Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol. 75 (2006) 25-71
15. Cowan C.M., Fan M.M., Fan J., Shehadeh J., Zhang L.Y., Graham R.K., Hayden M.R., and Raymond L.A. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J. Neurosci. 28 (2008) 12725-12735
16. Cummings D.M., André V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., and Levine M.S. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 29 (2009) 10371-10386
17. D'Ascenzo M., Fellin T., Terunuma M., Revilla-Sanchez R., Meaney D.F., Auberson Y.P., Moss S.J., and Haydon P.G. mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 104 (2007) 1995-2000
18. Ding J., Peterson J.D., and Surmeier D.J. Corticostriatal and thalamostriatal synapses have distinctive properties. J. Neurosci. 28 (2008) 6483-6492
19. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., and Stout J.C. Psychiatric symptoms in Huntington's disease before diagnosis: The Predict-HD study. Biol. Psychiatr. 62 (2007) 1341-1346
20. Fan M.M., and Raymond L.A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 81 (2007) 272-293
21. Fan M.M., Fernandes H.B., Zhang L.Y., Hayden M.R., and Raymond L.A. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J. Neurosci. 27 (2007) 3768-3779
22. Fernandes H.B., Baimbridge K.G., Church J., Hayden M.R., and Raymond L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 27 (2007) 13614-13623
23. Fusco F.R., Zuccato C., Tartari M., Martorana A., De March Z., Giampà C., Cattaneo E., and Bernardi G. Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. Eur. J. Neurosci. 18 (2003) 1093-1102
24. Gafni J., and Ellerby L.M. Calpain activation in Huntington's disease. J. Neurosci. 22 (2002) 4842-4849
25. Gafni J., Hermel E., Young J.E., Wellington C.L., Hayden M.R., and Ellerby L.M. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279 (2004) 20211-20220
26. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., and MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12 (2003) 497-508
27. Glykys J., and Mody I. The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J. Physiol. 582 (2007) 1163-1178
28. Goldberg Y.P., Nicholson D.W., Rasper D.M., Kalchman M.A., Koide H.B., Graham R.K., Bromm M., Kazemi-Esfarjani P., Thornberry N.A., Vaillancourt J.P., and Hayden M.R. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet. 13 (1996) 442-449
29. Gouix E., Léveillé F., Nicole O., Melon C., Had-Aissouni L., and Buisson A. Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Mol. Cell. Neurosci. 40 (2009) 463-473
30. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125 (2006) 1179-1191
31. Graham R.K., Slow E.J., Deng Y., Bissada N., Lu G., Pearson J., Shehadeh J., Leavitt B.R., Raymond L.A., and Hayden M.R. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis. 21 (2006) 444-455
32. Hardingham G.E., and Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 26 (2003) 81-89
33. Hardingham G.E., Fukunaga Y., and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5 (2002) 405-414
34. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., and Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 29 (2009) 3200-3205
35. Hines R.M., Wu L., Hines D.J., Steenland H., Mansour S., Dahlhaus R., Singaraja R.R., Cao X., Sammler E., Hormuzdi S.G., et al. Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression. J. Neurosci. 28 (2008) 6055-6067
36. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
37. Köhr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 326 (2006) 439-446
38. Lau C.G., and Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8 (2007) 413-426
39. Le Meur K., Galante M., Angulo M.C., and Audinat E. Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. J. Physiol. 580 (2007) 373-383
40. Leveille F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., and Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. Faseb J. 22 (2008) 4258-4271
41. Li L., Murphy T.H., Hayden M.R., and Raymond L.A. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 92 (2004) 2738-2746
42. Lozovaya N.A., Grebenyuk S.E., Tsintsadze T.Sh., Feng B., Monaghan D.T., and Krishtal O.A. Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus. J. Physiol. 558 (2004) 451-463
43. Massey P.V., Johnson B.E., Moult P.R., Auberson Y.P., Brown M.W., Molnar E., Collingridge G.L., and Bashir Z.I. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J. Neurosci. 24 (2004) 7821-7828
44. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., and Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153 (2008) 329-337
45. Milnerwood A.J., and Raymond L.A. Synaptic Abnormalities Associated with Huntington's disease. In: El-Husseini A., and Dityatev A. (Eds). Molecular Mechanisms of Synaotogenesis (2006), Springer, New York 457-469
46. Milnerwood A.J., and Raymond L.A. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J. Physiol. 585 (2007) 817-831
47. Milnerwood A.J., Cummings D.M., Dallérac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., and Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 15 (2006) 1690-1703
48. Murphy K.P.S.J., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 20 (2000) 5115-5123
49. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15 (2009) 1407-1413
50. Pacchioni A.M., Vallone J., Worley P.F., and Kalivas P.W. Neuronal pentraxins modulate cocaine-induced neuroadaptations. J. Pharmacol. Exp. Ther. 328 (2009) 183-192
51. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
52. Panov A.V., Lund S., and Greenamyre J.T. Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell. Biochem. 269 (2005) 143-152
53. Papadia S., and Hardingham G.E. The dichotomy of NMDA receptor signaling. Neuroscientist 13 (2007) 572-579
54. Papadia S., Soriano F.X., Léveillé F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 11 (2008) 476-487
55. Parsons C.G., Stöffler A., and Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53 (2007) 699-723
56. Pouladi M.A., Graham R.K., Karasinska J.M., Xie Y., Santos R.D., Petersén A., and Hayden M.R. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132 (2009) 919-932
57. Prybylowski K., Chang K., Sans N., Kan L., Vicini S., and Wenthold R.J. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47 (2005) 845-857
58. Reilly C.E. Wild-type huntingtin up-regulates BDNF transcription in Huntington's disease. J. Neurol. 248 (2001) 920-922
59. Scimemi A., Fine A., Kullmann D.M., and Rusakov D.A. NR2B-containing receptors mediate cross talk among hippocampal synapses. J. Neurosci. 24 (2004) 4767-4777
60. Seong I.S., Ivanova E., Lee J.M., Choo Y.S., Fossale E., Anderson M., Gusella J.F., Laramie J.M., Myers R.H., Lesort M., and MacDonald M.E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14 (2005) 2871-2880
61. Sergueeva O.A., Fedorov N.B., and Reymann K.G. An antagonist of glutamate metabotropic receptors, (RS)-alpha-methyl-4-carboxyphenylglycine, prevents the LTP-related increase in postsynaptic AMPA sensitivity in hippocampal slices. Neuropharmacology 32 (1993) 933-935
62. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., and Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 21 (2006) 392-403
63. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12 (2003) 1555-1567
64. Smeal R.M., Keefe K.A., and Wilcox K.S. Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum. Eur. J. Neurosci. 28 (2008) 2041-2052
65. Solomon A.C., Stout J.C., Johnson S.A., Langbehn D.R., Aylward E.H., Brandt J., Ross C.A., Beglinger L., Hayden M.R., Kieburtz K., et al., Predict-HD investigators of the Huntington Study Group. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 45 (2007) 1767-1776
66. Stanika R.I., Pivovarova N.B., Brantner C.A., Watts C.A., Winters C.A., and Andrews S.B. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc. Natl. Acad. Sci. USA 106 (2009) 9854-9859
67. Stocca G., and Vicini S. Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J. Physiol. 507 (1998) 13-24
68. Sugars K.L., Brown R., Cook L.J., Swartz J., and Rubinsztein D.C. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 279 (2004) 4988-4999
69. Tang T.S., Slow E., Lupu V., Stavrovskaya I.G., Sugimori M., Llinás R., Kristal B.S., Hayden M.R., and Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 102 (2005) 2602-2607
70. Thomas M.J., Malenka R.C., and Bonci A. Modulation of long-term depression by dopamine in the mesolimbic system. J. Neurosci. 20 (2000) 5581-5586
71. Tzingounis A.V., and Wadiche J.I. Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat. Rev. Neurosci. 8 (2007) 935-947
72. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., and Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 25 (2005) 4169-4180
73. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
74. Wellington C.L., Leavitt B.R., and Hayden M.R. Huntington disease: new insights on the role of huntingtin cleavage. J. Neural Transm. Suppl. (2000) 1-17
75. Wellington C.L., Ellerby L.M., Gutekunst C.A., Rogers D., Warby S., Graham R.K., Loubser O., van Raamsdonk J., Singaraja R., Yang Y.Z., et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22 (2002) 7862-7872
76. Whittaker V.P. Thirty years of synaptosome research. J. Neurocytol. 22 (1993) 735-742
77. Williams K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr. Drug Targets 2 (2001) 285-298
78. Wilson C.J., and Kawaguchi Y. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J. Neurosci. 16 (1996) 2397-2410
79. Wolf J.A., Moyer J.T., Lazarewicz M.T., Contreras D., Benoit-Marand M., O'Donnell P., and Finkel L.H. NMDA/AMPA ratio impacts state transitions and entrainment to oscillations in a computational model of the nucleus accumbens medium spiny projection neuron. J. Neurosci. 25 (2005) 9080-9095
80. Wu H.Y., Hsu F.C., Gleichman A.J., Baconguis I., Coulter D.A., and Lynch D.R. Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems. J. Biol. Chem. 282 (2007) 20075-20087
81. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell M., Schapira A., Orntoft T.F., et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10 (2001) 1829-1845
82. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
83. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., and Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 25 (2004) 469-479
84. Zhang H., Li Q., Graham R.K., Slow E., Hayden M.R., and Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 31 (2008) 80-88
85. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
86. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., and Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 52 (2005) 133-139